CAR-T trial deaths do not deter lupus patients hoping for a cure

Mavacamten showed sustained reduction in LVOT gradient in pediatric oHCM patients over 56 weeks, according to data presented at AHA 2026. The SCOUT-HCM trial, sponsored by Bristol-Myers Squibb, found significant improvements in efficacy endpoints with a favorable safety profile. Investigator Joseph Rossano discussed potential next steps for real-world studies. (BMY)

Amgen presented phase 3 trial results for dazodalibep in Sjögren's disease, showing both dosing schedules reduced systemic disease activity more than placebo. Novartis awaits an FDA decision on rival ianalumab. Amgen's second phase 3 trial, OASIZ-303, is ongoing. No FDA-approved therapies exist for Sjögren's, an autoimmune disease.

Novartis reported 108-week data on ianalumab at ACR Convergence 2026, showing improved disease activity in Sjögren’s Syndrome patients. Continuous 300 mg monthly treatment group saw ESSDAI score improvement of -7.5 points. Low disease activity rates rose to 65.1% in continuous-treatment group and 60.9% in placebo-switch group. Novartis seeks FDA decision in 2026.

Bristol Myers Squibb's mavacamten (Camzyos) showed sustained benefits in adolescents with oHCM at 56 weeks, per SCOUT-HCM trial data. Patients maintained reduced LVOT obstruction, with no LVEF below 50%. The FDA approved mavacamten for pediatric oHCM in September 2026. The drug is available only through the Camzyos REMS Program, requiring echocardiographic monitoring and dose adjustments.

Novartis reported that its Sjögren’s disease drug candidate, ianalumab, showed sustained improvements in systemic disease activity through week 108 of treatment, according to the NEPTUNUS extension study. Patients taking a 300 mg monthly dose experienced a reduction in disease activity.

Novartis reported two-year data from its Phase 3 study of ianalumab, showing continued improvements in Sjögren's disease activity. Patients on the drug saw increased reductions in disease activity and low disease activity rates. Adverse event rates were comparable between groups. Novartis expects a U.S. FDA decision this year, with no approved treatments for Sjögren's outside China.